The Future of Cell and Gene Therapy Manufacturing, Development, And Commercialization
Information
The Future of Cell and Gene Therapy Manufacturing, Development, And Commercialization
- A decade after the first cell and gene therapy was approved, the focus is on operationalizing therapies for larger patient populations
- Enhancing patient access through development and manufacturing of cost-effective and commercially successful programs
- Communication and advocacy for market access and reimbursements are key to ensuring that well-developed therapies with effective manufacturing models are appropriately priced and reimbursed
Chair Introduction
Matthew Hewitt, Vice President, Technical Officer, Cell & Gene Therapy & Biologics, Charles River Laboratories
9.00am Presentation: Development of Cell and Gene Therapies: Preclinical CRO perspective
- Overview of the discovery and development roadmaps of cell and gene therapies
- Key pitfalls and considerations during the development process
- Sharing benefits of partnering with Charles River, navigating through the entire process of developing those therapies
- Benefits of having an integrated development process
- Mitigation of unforeseen roadblocks during the development process
Gemma Moiset, Senior Advanced Modalities Group Leader, Charles River
9.15am Presentation: Delivering Next Generation CGT Manufacturing Solutions
- CGT manufacturing headwinds: the challenges
- Adoption of new technology to future-proof manufacturing
- Leveraging the ecosystem to enable success
Rodney Rietze, Co-Founder & Chief Executive Officer, iVEXSol
9.30am Presentation: A Decentralized CDMO Manufacturing Strategy For Future Readiness
Matthew Hewitt, Vice President, Technical Officer, Cell & Gene Therapy & Biologics, Charles River Laboratories
9.45am Presentation: Market Access and Reimbursements
Amritha Jaishankar, Executive Director, Cell and Gene Therapy Center, IQVIA
10.00am Panel Discussion
Joined by all session participants
